Head and Neck Cancer – Analysis and Management

Head Neck Cancer 1

Up until the present, there have been no predictive biomarkers or indicators for guiding HNSCC treatment. A survey report on precision medicine entitled, “Global Precision Medicine Market : Analysis and Forecast, 2017–2026” from BIS Research registered $43.59 billion in 2016. It is estimated to reach $141.70 billion by 2026, with an annual growth rate of 11.23%. The Personalized Medicine Coalition for diagnostic and targeted agents was $25 billion in 2015. 

“On a thumb rule, 30% of newly Cancer screened cases would account for HNSCC, the majority of men affected by it.”

Dr. Hemantkumar Nemade,Consultant Head and Neck, OncologistBasavatarakam Indo-AmericanCancer Hospital, Hyderabad

The biomarkers for precision medicine drugs (in numbers) were 5 in 2008 and went up to 132 in 2016. According to a survey by the Tufts Centre for Drug Development, 42% of drugs are in the pipeline plan and will be considered soon. Global investments in the next 5 years are likely to increase by 33% for precision medicine drugs, and immunotherapy drugs. There is a surge in the global market, where the growth was $108 billion in 2016 and is nearly estimated to be $200 billion . . .

This exclusive content is reserved for our valued members. Kindly log in or sign up to enjoy full access and delve into the complete article.
Priya Subramani

Priya Subramani

A post graduate in Nanotechnology, seamlessly integrates her expertise in engineering and research to craft compelling narratives that bridge the realms of science and technology, enlightening readers with her captivating writing.